Current Surgical Treatment in Melanoma

Current Problems in Cancer

Volumn 35, Issue 4, 2011, Pages 173-184

  Faries, Mark B ^a   Ariyan, Stephan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; CANCER VACCINE;

ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DISTANT METASTASIS; DRUG RESISTANCE; HIGH RISK POPULATION; HUMAN; LYMPH NODE DISSECTION; MELANOMA; PATIENT SELECTION; PRIMARY TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENTINEL LYMPH NODE; SKIN CANCER; SURVIVAL RATE; ULTRASOUND; WIDE EXCISION;

ADULT; AGED; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; SKIN NEOPLASMS;

EID: 80052662597     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2011.07.002     Document Type: Article

References (52)

1. Cochran A.J. Studies of the melanocytes of the epidermis adjacent to tumors. J Invest Dermatol 1971, 57:38-43.
2. Veronesi U., Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991, 126:438-441.
3. Khayat D., Rixe O., Martin G., et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003, 97:1941-1946.
4. Cohn-Cedermark G., Rutqvist L.E., Andersson R., et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000, 89:1495-1501.
5. Balch C.M., Urist M.M., Karakousis C.P., et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993, 218:262-267. [Discussion 267-9].
6. Thomas J.M., Newton-Bishop J., A'Hern R., et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004, 350:757-766.
7. Ringborg U., Brahme E.M., Drewiecki K. Randomized trial of a resection margin of 2 cm versus 4 cm for cutaneous malignant melanoma with a tumor thickness of more than 2 mm. 6th World Congress on Melanoma 2005, Vancouver.
8. Coit D.G., Andtabacka R., Anker C.J., et al. NCCN Clinical Practice Guidelines in Oncology. NCCN Guidelines Version 3. Melanoma 2011, Accessed on April 18, 2011. http://www.ncccn.org/professionals/physician_gls/f_guidelines.asp.
9. Posther K.E., Selim M.A., Mosca P.J., et al. Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. Ann Surg Oncol 2006, 13:728-739.
10. McLeod G., Davis N., Sober A. A history of melanoma from Hunter to Clark. Cutaneous Melanoma 2003, 1-11. Quality Medical Publishing, St. Louis (MO). 4th edition. C. Balch (Ed.).
11. Cascinelli N., Morabito A., Santinami M., et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998, 351:793-796.
12. Sim F.H., Nelson T.E., Pritchard D.J. Malignant melanoma: Mayo Clinic experience. Mayo Clin Proc Mayo Clin 1997, 72:565-569.
13. Veronesi U., Adamus J., Bandiera D.C., et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977, 297:627-630.
14. Balch C., Soong S., Ross M., et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0-4.0 mm). Ann Surg Oncol 2000, 7:87-97.
15. Holmes E.C., Moseley H.S., Morton D.L., et al. A rational approach to the surgical management of melanoma. Ann Surg 1977, 186:481-490.
16. Wong J.H., Cagle L.A., Morton D.L. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg 1991, 214:637-641.
17. Morton D.L., Wen D.R., Wong J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127:392-399.
18. Morton D.L., Cochran A.J., Thompson J.F., et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005, 242:302-311.
19. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355:1307-1317.
20. Gershenwald J.E., Mansfield P.F., Lee J.E., et al. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 2000, 7:160-165.
21. Essner R., Chung M.H., Bleicher R., et al. Prognostic implications of thick (>or=4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol 2002, 9:754-761.
22. Wong S.L. The role of sentinel lymph node biopsy in the management of thin melanoma. Am J Surg 2005, 190:196-199.
23. Wright B.E., Scheri R.P., Ye X., et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg 2008, 143:892-899. [Discussion 899-900].
24. Agnese D.M., Abdessalam S.F., Burak W.E., et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003, 134:542-547. [Discussion 547-8].
25. Lowe J.B., Hurst E., Moley J.F., et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol 2003, 139:617-621.
26. Bedrosian I., Faries M.B., Guerry D., et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol 2000, 7:262-267.
27. Bleicher R.J., Essner R., Foshag L.J., et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003, 21:1326-1331.
28. Hershko D.D., Robb B.W., Lowy A.M., et al. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol 2006, 93:279-285.
29. Kesmodel S.B., Karakousis G.C., Botbyl J.D., et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005, 12:449-458.
30. Oliveira Filho R.S., Ferreira L.M., Biasi L.J., et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 2003, 36:347-350.
31. Puleo C.A., Messina J.L., Riker A.I., et al. Sentinel node biopsy for thin melanomas: which patients should be considered?. Cancer Control 2005, 12:230-235.
32. Stitzenberg K.B., Groben P.A., Stern S.L., et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol 2004, 11:900-906.
33. Karakousis G.C., Gimotty P.A., Botbyl J.D., et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol 2006, 13:533-541.
34. Naruns P.L., Nizze J.A., Cochran A.J., et al. Recurrence potential of thin primary melanomas. Cancer 1986, 57:545-548.
35. Schmid-Wendtner M.H., Baumert J., Eberle J., et al. Disease progression in patients with thin cutaneous melanomas (tumour thickness < or = 0.75 mm): clinical and epidemiological data from the Tumour Center Munich 1977-98. Br J Dermatol 2003, 149:788-793.
36. Faries M.B., Wanek L.A., Elashoff D., et al. Predictors of occult nodal metastasis in patients with thin melanoma. Arch Surg 2010, 145:137-142.
37. Paek S.C., Griffith K.A., Johnson T.M., et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007, 109:100-108.
38. Voit C., Van Akkooi A.C., Schafer-Hesterberg G., et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. J Clin Oncol Off J American Society Of Clinical Oncology 2010, 28:847-852.
39. Thompson J.F., Haydu L.E., Uren R.F., et al. Preoperative Ultrasound Assessment of Sentinel Nodes in Melanoma Patients Does Not Provide Reliable Staging: Results from a Large Multicenter Trial 2011, In Society of Surgical Oncology, San Antonio, TX.
40. Morton D., Cochran A., Thompson J.F. Authors' reply regarding: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2007, 356:419-421.
41. Altstein L.L., Li G., Elashoff R.M. A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial. Stat Med 2011, 30:709-717.
42. Faries M.B., Thompson J.F., Cochran A., et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial. Ann Surg Oncol 2010, I17:3324-3329.
43. Ollila D.W., Morton D.L. Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin North Am 1998, 8:183-196.
44. Faries M.B., Bleicher R.J., Ye X., et al. Lymphatic mapping and sentinel lymphadenectomy for primary and metastatic pulmonary malignant neoplasms. Arch Surg 2004, 139:870-876. [Discussion 876-7].
45. Pawlik T., Zorzi D., Abdalla E., et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 2006, 13:712-720.
46. Rose D., Essner R., Hughes T., et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit Experience. Arch Surg 2001, 136:950-955.
47. Wood T.F., DiFronzo L.A., Rose D.M., et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival?. Ann Surg Oncol 2001, 8:658-662.
48. Ollila D.W., Essner R., Wanek L.A., et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 1996, 131:975-979.
49. Sosman J.A., Moon J., Tuthill R.J., et al. A phase 2 trial of complete resection for stage IV melanoma: Results of Southwest Oncology Group Clinical Trial. Cancer 2011, [Epub ahead of print].
50. Morton D., Mozzillo N., Thompson J., et al. An international, randomized, double-blind, phase 3 study of the specific active immunotherapy agent, Onamelatucel-L (Canvaxin), compared to placebo as post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol 2006, 13:5s.
51. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
52. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.